New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes http://finance.yahoo.com/news/New-Phase-2-Data-Published-in-prnews-382459161.html?x=0&.v=1